

## HR 5239

### Prescription Drug Price Reporting Act

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Nov 21, 2019

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Nov 22, 2019)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/5239>

## Sponsor

**Name:** Rep. Joyce, David P. [R-OH-14]

**Party:** Republican • **State:** OH • **Chamber:** House

## Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Gonzalez, Anthony [R-OH-16]	R · OH		Dec 19, 2019

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Nov 22, 2019

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

No related bills are listed.

## Summary (as of Nov 21, 2019)

### Prescription Drug Price Reporting Act

This bill requires that all prescription drug manufacturers submit certain information for every drug marketed in the United States to the Department of Health and Human Services (HHS). Specifically, manufacturers must provide information about cost, pricing, and rebates. Manufacturers are also required to submit any price changes to a prescription drug at least 30 days in advance.

HHS must make this information available through a public database that enables consumers to subscribe to price change notifications for different types of prescriptions drugs.

## **Actions Timeline**

---

- **Nov 22, 2019:** Referred to the Subcommittee on Health.
- **Nov 21, 2019:** Introduced in House
- **Nov 21, 2019:** Referred to the House Committee on Energy and Commerce.